These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26865521)

  • 1. Spinal muscular atrophy: A preliminary result toward new therapy.
    Nevo Y; Wang C
    Neurology; 2016 Mar; 86(10):884-5. PubMed ID: 26865521
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intrathecal Nursinersen Therapy in Children with Spinal Muscular Atrophy and Spinal Deformities].
    Lorenz HM; Kühnle I; Edler J; Hobbiebrunken E; Wilichowski E; Tsaknakis K; Wilken B; Braunschweig L; Hell AK
    Klin Padiatr; 2018 Jul; 230(4):231-233. PubMed ID: 29378349
    [No Abstract]   [Full Text] [Related]  

  • 3. Nusinersen Use in Spinal Muscular Atrophy.
    Pediatrics; 2019 Jan; 143(1):. PubMed ID: 30584063
    [No Abstract]   [Full Text] [Related]  

  • 4. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 5. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
    Corey DR
    Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
    [No Abstract]   [Full Text] [Related]  

  • 6. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen.
    Machacek ME; Gogakos T; Fletcher MC; Lunderville KA; Swoboda KJ; Sohani AR
    Int J Lab Hematol; 2021 Jun; 43(3):e104-e106. PubMed ID: 33201586
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
    Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
    Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
    Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
    J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
    Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
    Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
    JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid treatment in six patients with spinal muscular atrophy.
    Tsai LK; Yang CC; Hwu WL; Li H
    Eur J Neurol; 2007 Dec; 14(12):e8-9. PubMed ID: 18028187
    [No Abstract]   [Full Text] [Related]  

  • 13. Spinal muscular atrophy approval boosts antisense drugs.
    Dolgin E
    Nat Biotechnol; 2017 Feb; 35(2):99-100. PubMed ID: 28178250
    [No Abstract]   [Full Text] [Related]  

  • 14. Camptocormia as an onset symptom of myasthenia gravis.
    Sato T; Natori T; Hata T; Yamashiro N; Shindo K; Takiyama Y
    Neurol Sci; 2017 Mar; 38(3):515-516. PubMed ID: 27812759
    [No Abstract]   [Full Text] [Related]  

  • 15. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 16. Spinraza-a rare disease success story.
    Prakash V
    Gene Ther; 2017 Sep; 24(9):497. PubMed ID: 28963567
    [No Abstract]   [Full Text] [Related]  

  • 17. Inflammatory myopathy presenting as head drop.
    Riaudel T; Khatchatourian L; Chevalet P; Pichierri S; Mussini JM; Berrut G
    Age Ageing; 2013 Jan; 42(1):132. PubMed ID: 22832378
    [No Abstract]   [Full Text] [Related]  

  • 18. Myasthenia gravis can cause camptocormia.
    Kataoka H; Kiriyama T; Ueno S
    J Neurol Neurosurg Psychiatry; 2012 Apr; 83(4):469-70. PubMed ID: 21933949
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic advances in 5q-linked spinal muscular atrophy.
    Reed UC; Zanoteli E
    Arq Neuropsiquiatr; 2018 Apr; 76(4):265-272. PubMed ID: 29742241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compilation of online resources of relevance to 'Spinraza and advanced therapies: a stakeholder special' issue of Gene Therapy.
    Prakash V; Yáñez-Muñoz RJ
    Gene Ther; 2017 Sep; 24(9):599. PubMed ID: 28963566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.